오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 116.96 mg/ml (equivalent: amoxicillin, qty 100 mg/ml) - oral liquid, powder for - excipient ingredients: crospovidone; xanthan gum; sodium benzoate; hydrophobic colloidal silica anhydrous; magnesium stearate; aspartame; carmellose sodium; flavour - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli (see microbiology). respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbiology), p.mirabilis and s.faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxil may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium, quantity: 56.568 mg/ml (equivalent: phenoxymethylpenicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: sucrose; sodium benzoate; saccharin sodium; flavour; colour - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms such as penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea. for the prevention of bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium, quantity: 28.284 mg/ml (equivalent: phenoxymethylpenicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: sucrose; sodium benzoate; saccharin sodium; colour; flavour - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms such as penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea. for the prevention of bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 114.82 mg/ml (equivalent: amoxicillin, qty 100 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 28.77 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin, quantity: 1 g (equivalent: vancomycin, qty 1 million iu) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide; hydrochloric acid - indicated for potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins. severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (eg e faecalis), only in combination with an aminoglycoside. for the treatment of diphtheroid endocarditis. in combination with rifampin, an aminoglycoside or both in early-onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids. in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft tissue infections. wh

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 1.048 g - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: - respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present; - genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci; - skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant), and group a beta-haemolytic streptococci and other strains of streptococci; - bone and joint infections due to staph. aureus; - septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.; - endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.